Please login to the form below

PD-L1/ PD-1 inhibitor

This page shows the latest PD-L1/ PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Bintrafusp alfa is part of a new wave of bispecific antibodies that are currently being developed by a number of companies as potential successors to the PD-1/PD-L1 inhibitor ... class. The molecule is designed to simultaneously target two

Latest news

Tecentriq misses the mark in advanced ovarian cancer

PD-L1 inhibitor failed to improved progression-free survival. Roche’s Genentech division has reported that Tecentriq, plus Avastin, was unable to improve progression-free survival as a front-line treatment ... The FDA approval for Imfinzi makes AZ’s
AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq

The green light makes Imfinzi (durvalumab) the first PD-1/PD-L1 inhibitor to challenge Roche’s Tecentriq (atezolizumab) in ES-SCLC, which became the first checkpoint inhibitor to be approved ... In ES-SCLC, additional heavyweight competition could be
BMS scores first oesophageal cancer nod for Opdivo in Japan

The approval in oesophageal cancer is particularly important for BMS as it continues to fight for its place in the PD-1/L1 inhibitor class, while Merck &Co’s Keytruda (pembrolizumab) ... The MHLW approved Opdivo based on the results from the phase 3
FDA sets June decision date for Tecentriq monotherapy in NSCLC

Tecentriq also beat chemotherapy in terms of patients who experienced grade 3-4 treatment-related adverse events, with 12.9% of people treated with the PD-L1 inhibitor experiencing one compared ... However, the NSCLC therapy area is dominated by
Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death. Merck &Co/MSD has chalked up a clinical trial win for its PD-1 inhibitor Keytruda in triple-negative breast cancer that ... Keytruda is the top-selling PD-1/PD-L1 inhibitor worldwide thanks to

More from news
Approximately 1 fully matching, plus 59 partially matching documents found.

Latest Intelligence

Immuno-oncology in 2019: the rapid evolution continues

cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Management: Competitive Salary Offered

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Group Account Director, Healthcare Advertising/ Brand comms, Lon...: 8 month contract up to £90K

Publications Director: Competitive Salary

Account Manager - Creative Healthcare Communications - South Wes...: Excellent Remuneration

Medical Editor: Competitive Salary

Senior & Principal Medical Writers Medical Communications - ...: Salary TBC

Senior Account Manager/ Account Director: Competitive Salary Offered

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Senior & Principal Medical Writer: Competitive Salary Offered

Associate Account Director: Competitive Salary

Senior Medical Writer: Competitive Salary

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Head of Strategic Planning, Healthcare Advertising/ Brand comms,...: Six figure salary

Account Manager: Competitive Salary

Senior Account Executive: Competitive Salary

Editorial Traffic Manager, Medical Communications Agency, London...: up to £45K

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Medical Writers (All levels) Editorial / Scientific Leads & ...: Highly Competitive Remuneration packages

PMHub

Add my company

Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency: There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown: Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it: If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....

Email:
Password:

Please login to the form below

PD-L1/ PD-1 inhibitor

COVID-19 Updates and Daily News

Featured jobs

Quick links